Remission in schizophrenia: Critical and systematic review

Harvard Review of Psychiatry

Volumn 20, Issue 6, 2012, Pages 281-297

  Alaqeel, Bandar ^a,b   Margolese, Howard C ^c  

^a Allan Memorial Institute   (Canada)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c NONE

Author keywords

First episode psychosis; Multiple episode schizophrenia; Remission; Remission consen sus criteria; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; FOLLOW UP; HUMAN; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCHIZOPHRENIA; SOCIAL COGNITION; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; HALLUCINATIONS; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84870867141     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673229.2012.747804     Document Type: Article

References (70)

1. Frese FJ, III, Knight EL, Saks E. Recovery from schizophrenia: with views of psychiatrists, psychologists, and others diagnosed with this disorder. Schizophr Bull 2009;35:370-80.
2. Adityanjee, Aderibigbe YA, Theodoridis D, Vieweg WVR. Dementia praecox to schizophrenia: the first 100 years. Psychiatry Clin Neurosci 1999;53:437-48.
3. Andreasen NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiatry 1999;56:781-7.
4. Leucht S, Kane JM. Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. J Clin Psychiatry 2006;67:1813-4.
5. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-9.
6. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry 2011;24:114-21.
7. Curtis CE, Calkins ME, Grove WM, Feil KJ, Iacono WG. Saccadic disinhibition in patients with acute and remitted schizophrenia and their first-degree biological relatives. Am J Psychiatry 2001;158:100-6.
8. Yen CF, Chen CS, Yeh ML, Yen JY, Ker JH, Yang SJ. Comparison of insight in patients with schizophrenia and bipolar disorder in remission. J Nerv Ment Dis 2002;190:847-9.
9. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76.
10. Amminger GP, Resch F, Mutschlechner R, Friedrich MH, Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc Psychiatry 1997;6:212-8.
11. Eaton WWPD, Thara RMD, Federman ESD, Tien AMD. Remission and relapse in schizophrenia: the Madras Longitudinal Study. J Nerv Ment Dis 1998;186:357-63.
12. Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry 2000;157:808-15.
13. Emsley R, Rabinowitz J, Medori R. Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007;89:129-39.
14. Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes. Schizophr Res 2006;86:300-8.
15. Miles AA, Heinrichs RW, Ammari N. "Real world" functioning in schizophrenia patients and healthy adults: assessing validity of the Multidimensional Scale of Independent Functioning. Psychiatry Res 2011;186:123-7.
16. Opler M, Yang L, Caleo S, Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007;7:35.
17. Llorca PM, Lançon C, Lancrenon S, et al. The "Functional Remission of General Schizophrenia" (FROGS) scale: development and validation of a new questionnaire. Schizophr Res 2009;113:218-25.
18. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2007;33:792-6.
19. Kane JM, Leucht S. Issues in psychopharmacology. Schizophr Bull 2008;34:258.
20. Resnick SG, Fontana A, Lehman AF, Rosenheck RA. An empirical conceptualization of the recovery orientation. Schizophr Res 2005;75:119-28.
21. Opler MG, Yang LH, Caleo S, Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007;7:35.
22. Menezes NM, Malla AM, Norman RM, Archie S, Roy P, Zipursky RB. A multi-site Canadian perspective: examining the functional outcome from first-episode psychosis. Acta Psychiatr Scand 2009;120:138-46.
23. Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsy-chopharmacol 2009;12:1233-48.
24. Uçok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res 2011;189:33-7.
25. Remington G, Kapur S. Remission: what's in a name? Am J Psychiatry 2005;162:2393-4.
26. Docherty JP, Bossie CA, Lachaux B, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 2007;22:51-5.
27. Ciudad A, Alvarez E, Bobes J, San L, Polavieja P, Gilaberte I. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr Res 2009;108:214-22.
28. Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol 2009;23:436-41.
29. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJH, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006;67:1707-12.
30. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Pre-morbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry 2006;189:31-5.
31. Ceskova E, Radovan P, Tomas K, Hana K. One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters). Neuropsychiatr Dis Treat 2007;3:153-60.
32. Ceskova E, Prikryl R, Kasparek T. Outcome in males with firstepisode schizophrenia: 7-year follow-up. World J Biol Psychiatry 2011;12:66-72.
33. Emsley R, Oosthuizen P, Koen L, Niehaus DJH, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psy-chopharmacol 2008;23:325-31.
34. Addington J, Addington D. Symptom remission in first episode patients. Schizophr Res 2008;106:281-5.
35. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008;41:125-8.
36. Petersen L, Thorup A, Oqhlenschlaeger J, et al. Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS trial. Can J Psychiatry 2008;53:660-70.
37. Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsy-chotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 2009;115:97-103.
38. Uçok A, Serbest S, Kandemir PE. Remission after first-episode schizophrenia: results of a long-term follow-up. Psychiatry Res 2011;189:33-7.
39. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005;77:215-27.
40. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone: analysis of long-term efficacy. J Psychophar-macol 2005;19:15-21.
41. Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. Longterm remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Ther 2008;46:14-22.
42. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 2007;94:99-106.
43. Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007;95: 143-50.
44. Eberhard J, Levander S, Lindstrom E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry 2009;50:200-8.
45. Rossi A, Bagala A, Del Curatolo V, et al. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharma-col 2009;24:574-83.
46. Botha U, Koen L, Joska J, Hering L, Oosthuizen P. Assessing the efficacy of a modified assertive community-based treatment programme in a developing country. BMC Psychiatry 2010;10:73.
47. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment. Eur Psychiatry 2010;25: 220-9.
48. Meesters PD, Comijs HC, de Haan L, et al. Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia. Schizophr Res 2011;126:237-44.
49. Lasser RA, Nasrallah H, Helldin L, et al. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res 2007;96:223-31.
50. De Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007;92:68-73.
51. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:91-5.
52. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-76.
53. Robinson DG, Woerner MG, Alvir JMJ, etal. Predictors of treatment response from a first episode of schizophrenia or schizoaf-fective disorder. Am J Psychiatry 1999;156:544-9.
54. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005;62:1305-12.
55. Thompson J, Berk M, Dean O, et al. Who's left? Symptoms of schizophrenia that predict clinical trial dropout. Hum Psy-chopharmacol 2011;26:609-13.
56. Menezes NM, ArenovichT, Zipursky RB.A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006;36:1349-62.
57. Schennach R, Obermeier M, Meyer S, et al. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv 2012;63:87-90.
58. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2011;Nov 29 [Epub ahead of print].
59. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
60. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-90.
61. Kay SR, Flszbein A, Opfer LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
62. Stauffer VL, Case M, Kinon BJ, et al. Early response to antipsy-chotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 2011;187:42-8.
63. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60: 1228-35.
64. Masand P, O'Gorman C, Mandel FS. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res 2011;126:174-83.
65. Leucht S, Engel RR. The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. Neuropsychopharmacology 2005;31:406-12.
66. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand 2009;119:7-14.
67. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003;107:16-23.
68. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006;20:293-301.
69. van Os J, Drukker M, Campo J, Meijer J, Bak M, Delespaul P. Validation of remission criteria for schizophrenia. Am J Psychiatry 2006;163:2000-2.
70. Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ. Switching from risperidone to olanzapine in aone-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin 2008;24:1399-405.